Danny Butler, MD
Internal Medicine · Paducah, KYNPI 1003999251
Payments from drug & device makers
Across 245 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$667
- AbbVie$610
- Amgen$367
- Boehringer Ingelheim$357
- Pfizer$260
- Lilly USA, LLC$236
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,14199%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $667 |
| AbbVie(2 entities) | 35 | $610 |
| Amgen(2 entities) | 24 | $367 |
| Boehringer Ingelheim | 26 | $357 |
| Pfizer | 18 | $260 |
| Lilly USA, LLC | 16 | $236 |
| Novo Nordisk | 11 | $187 |
| Novartis | 10 | $152 |
| Biogen | 4 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $119 |
| Avanir Pharmaceuticals, Inc. | 5 | $109 |
| Eisai Inc. | 5 | $89 |
| Medtronic(2 entities) | 3 | $83 |
| Johnson & Johnson | 6 | $82 |
| Merck | 5 | $72 |
| Exact Sciences | 3 | $60 |
| Shire North American Group Inc | 3 | $48 |
| Astellas Pharma US Inc | 3 | $42 |
| Amarin Pharma, Inc. | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Ironshore Pharmaceuticals Inc. | 1 | $38 |
| Abbott | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Bayer | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$105
How this compares
$4,168 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 516 | $397,119 |
| MounjaroTirzepatide | 146 | $158,430 |
| OzempicSemaglutide | 108 | $127,591 |
| XareltoRivaroxaban | 161 | $124,421 |
| JardianceEmpagliflozin | 145 | $112,692 |
| FarxigaDapagliflozin Propanediol | 106 | $112,082 |
| TrulicityDulaglutide | 66 | $93,481 |
| JanuviaSitagliptin Phosphate | 75 | $86,360 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $42,981 |
| EntrestoSacubitril/Valsartan | 50 | $42,426 |
| MyrbetriqMirabegron | 45 | $38,102 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $32,888 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $26,908 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $26,241 |
| Repatha SureclickEvolocumab | 25 | $24,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $260 | $397,119516 claims |
| Lilly USA, LLCMounjaro, Trulicity | $236 | $251,911212 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $357 | $147,260190 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $667 | $144,969147 claims |
| Johnson & JohnsonXarelto, Invokana | $82 | $136,965179 claims |
| Novo NordiskOzempic | $187 | $127,591108 claims |
| MerckJanuvia | $72 | $86,36075 claims |
| NovartisEntresto | $152 | $42,42650 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $38,10245 claims |
| AbbVieSynthroid, Linzess | $610 | $30,999296 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $109 | $26,90824 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Multaq | $119 | $24,04526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Paducah
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Ryan FrazinePaducah$38K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.